Stephen Marburg - Metuchen NJ Richard L. Tolman - Warren NJ Peter J. Kniskern - Lansdale PA William J. Miller - North Wales PA Arpi Hagopian - Lansdale PA Charlotte C. Ip - Blue Bell PA John P. Hennessey - Dublin PA Dennis J. Kubek - Salem WV Pamela D. Burke - Lansdale PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07K 1702 A61K 39385
US Classification:
530404
Abstract:
A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.